Evidence map›Paper›PMID 21698426›Full record

ReviewJournal of molecular medicine (Berlin, Germany)2011

Nickel allergies: paying the Toll for innate immunity.

Marc Schmidt, Matthias Goebeler

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular medicine (Berlin, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Innate immune reactions in septic and aseptic osteolysis around hip implants.Journal of long-term effects of medical implants · 2014
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Marc SchmidtDepartment of Dermatology, Justus-Liebig-University Giessen, Gaffkystr. 14, 35392, Giessen, Germany. marc.schmidt@derma.med.uni-giessen.de
Matthias Goebeler
University of Giessen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergic contact hypersensitivity responses to the transition metal nickel (Ni(2+)) affect millions of people worldwide despite extensive legislatory efforts to ban the use of Ni(2+) in products coming into direct contact with the skin. Like other contact allergens, Ni(2+) triggers a T lymphocyte-driven delayed-type hypersensitivity reaction that is characterized by leukocyte infiltration at sites of allergen exposure. The last years have revealed that besides a hapten-specific T cell response, Ni(2+) can also directly trigger an innate immune response in resident skin cells that is necessary for mounting an allergic hypersensitivity reaction to Ni(2+). Recently, the receptor for the bacterial membrane component lipopolysaccharide, Toll-like receptor 4, has been identified as the crucial mediator of the innate immune response to Ni(2+), demonstrating that Ni(2+) employs signaling components of the bacterial defense system to elicit its allergic reactions. Here, we provide an overview of Ni(2+)-induced signaling events that have been implicated in contributing to the hypersensitivity response to this transition metal. We briefly review the causes and genetic predisposition fostering allergic responses to Ni(2+) and discuss potential therapeutic and prophylactic strategies and chances evolving from the novel insights into the molecular basis of this disease.

Indexed as

Amino Acid SequenceAnimalsDermatitis, ContactHumansImmunity, InnateInflammationMolecular Sequence DataNickelSignal TransductionToll-Like ReceptorsNickelToll-Like Receptors

Identifiers

PMID21698426
OpenAlexW1985054391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.